{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:00:01Z","timestamp":1790773201545,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delgocitinib is a topical, pan-Janus kinase (JAK) inhibitor. Use of delgocitinib ointment 0.5% has shown efficacy in treatment of atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the dose\u2013response relationship, efficacy and safety of delgocitinib cream in adults with mild to severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase IIb trial (NCT03725722), adults with mild to severe AD were randomized 1 : 1 : 1 : 1 : 1 to delgocitinib cream 1, 3, 8 or 20\u2005mg g\u22121 or cream vehicle applied twice daily for 8 weeks. The primary endpoint was change from baseline to week 8 in Eczema Area and Severity Index (EASI) score. Secondary endpoints included Validated Investigator\u2019s Global Assessment for AD treatment success (vIGA-AD TS) and achievement of EASI 75 (\u2265 75% improvement in EASI from baseline).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 251 patients were randomized (delgocitinib cream groups, n = 201; cream vehicle group, n = 50). At week 8, treatment with delgocitinib cream resulted in dose-dependent changes in EASI from baseline vs. cream vehicle (\u22125.0 for 1\u2005mg\u2005g\u22121, \u22124.9 for 3\u2005mg g\u22121, \u22125.8 for 8\u2005mg g\u22121 and \u22127.6 for 20\u2005mg g\u22121 vs. \u22121.9 for cream vehicle; all delgocitinib cream groups P &amp;lt; 0.05). A greater proportion of patients treated with delgocitinib achieved vIGA-AD TS [18% (n = 9\/49) for 1\u2005mg g\u22121, 29% (n = 14\/48) for 3\u2005mg g\u22121, 30% (n = 15\/50) for 8\u2005mg g\u22121 and 48% (n = 24\/50) for 20\u2005mg g\u22121] than those using cream vehicle (10%, n = 5\/48) at week 8. EASI 75 was achieved by 41% of patients (n = 20\/49) in the 1\u2005mg g\u22121 group, 44% (n = 21\/48) in the 3\u2005mg g\u22121 group, 56% (n = 28\/50) in the 8\u2005mg g\u22121 group, 66% (n = 33\/50) in the 20\u2005mg g\u22121 group and 21% (n = 10\/48) in the cream vehicle group at week 8. Incidence of adverse events was similar with delgocitinib cream (44.5%, n = 89\/200) and cream vehicle (56%, n = 28\/50).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with delgocitinib cream was more effective than cream vehicle in a dose\u2013response manner. Delgocitinib cream was well tolerated and no safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag296","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:37:14Z","timestamp":1784633834000},"source":"Crossref","is-referenced-by-count":0,"title":["Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomized phase IIb trial"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I","family":"Silverberg","sequence":"first","affiliation":[{"name":"Department of Dermatology, The George Washington University School of Medicine and Health Sciences , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-0199","authenticated-orcid":false,"given":"Dedee F","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marni C","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026093008264957900_ljag296-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"2026093008264957900_ljag296-B2","first-page":"S115","article-title":"Overview of atopic dermatitis","volume":"23","author":"Avena-Woods","year":"2017","journal-title":"Am J Manag Care"},{"key":"2026093008264957900_ljag296-B3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2026093008264957900_ljag296-B4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2337\/dc18-2158","article-title":"Association between topical corticosteroid use and type 2 diabetes in two European population-based adult cohorts","volume":"42","author":"Andersen","year":"2019","journal-title":"Diabetes Care"},{"key":"2026093008264957900_ljag296-B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2020.4968","article-title":"Association of potent and very potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures","volume":"157","author":"Egeberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026093008264957900_ljag296-B6","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/exd.14389","article-title":"Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease","volume":"30","author":"Sims","year":"2021","journal-title":"Exp Dermatol"},{"key":"2026093008264957900_ljag296-B7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","article-title":"Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis","volume":"12","author":"Haddad","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026093008264957900_ljag296-B8","first-page":"19","article-title":"JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026093008264957900_ljag296-B9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergol Int"},{"key":"2026093008264957900_ljag296-B10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026093008264957900_ljag296-B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"2026093008264957900_ljag296-B12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2026093008264957900_ljag296-B13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm Res"},{"key":"2026093008264957900_ljag296-B14","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: A systematic review","volume":"11","author":"Tsiogka","year":"2022","journal-title":"J Clin Med"},{"key":"2026093008264957900_ljag296-B15","author":"Food and Drug Administration"},{"key":"2026093008264957900_ljag296-B16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026093008264957900_ljag296-B17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp Dermatol"},{"key":"2026093008264957900_ljag296-B18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2026093008264957900_ljag296-B19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2026093008264957900_ljag296-B20","author":"Japan Tobacco Inc. (JT)"},{"key":"2026093008264957900_ljag296-B21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials","volume":"404","author":"Bissonnette","year":"2024","journal-title":"Lancet"},{"key":"2026093008264957900_ljag296-B22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S2352-4642(26)00098-2","article-title":"Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial","volume":"10","author":"Molin","year":"2026","journal-title":"Lancet Child Adolesc Health"},{"key":"2026093008264957900_ljag296-B23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","article-title":"Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials","volume":"93","author":"Gooderham","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026093008264957900_ljag296-B24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026093008264957900_ljag296-B25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjd.21037","article-title":"The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial","volume":"187","author":"Worm","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026093008264957900_ljag296-B26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026093008264957900_ljag296-B27"},{"key":"2026093008264957900_ljag296-B28","author":"Food and Drug Administration"},{"key":"2026093008264957900_ljag296-B29","author":"LEO Pharma Inc."},{"key":"2026093008264957900_ljag296-B30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/bjd.21615","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): a clinical outcome measure for the severity of atopic dermatitis","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026093008264957900_ljag296-B31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.19457","article-title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026093008264957900_ljag296-B32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026093008264957900_ljag296-B33","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis","volume":"78","author":"Alves","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026093008264957900_ljag296-B34","author":"European Medicines Agency"},{"key":"2026093008264957900_ljag296-B35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.15271","article-title":"A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients","volume":"176","author":"Zhao","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026093008264957900_ljag296-B36","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","article-title":"Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026093008264957900_ljag296-B37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(25)00001-7","article-title":"Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial","volume":"405","author":"Gim\u00e9nez-Arnau","year":"2025","journal-title":"Lancet"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag296\/69772913\/ljag296.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag296\/69772913\/ljag296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:26:58Z","timestamp":1790771218000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag296\/8739678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag296","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"ljag296"}}